Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HPN328 |
Synonyms | |
Therapy Description |
HPN328 is a tri-specific T-cell activating construct (TriTAC) consisting of an antibody targeting DLL3 and a single-chain fragment targeting CD3, which potentially induces T-cell recruitment and inhibits growth of DLL3-expressing tumors (PMID: 38670552). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HPN328 | HPN-328|DLL3/CD3e TriTAC HPN328|Anti-DLL3 T-cell Engager HPN328|MK-6070 | DLL3 Antibody 6 | HPN328 is a tri-specific T-cell activating construct (TriTAC) consisting of an antibody targeting DLL3 and a single-chain fragment targeting CD3, which potentially induces T-cell recruitment and inhibits growth of DLL3-expressing tumors (PMID: 38670552). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04471727 | Phase Ib/II | Atezolizumab + HPN328 HPN328 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | Recruiting | USA | 0 |